Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres

Danjo, Atsushi; Yamaguchi, Kuniko; Fujimoto, Kazuma; Saitoh, Toshihito; Inamori, Masahiko; Ando, Takashi; Shimatani, Tomohiko; Adachi, Kyoichi; Kinjo, Fukunori; Kuribayashi, Shiko; Mitsufuji, Shoji; Fujiwara, Yasuhiro; Koyama, Shigeki; Akiyama, Junichi; Takagi, Atsushi; Manabe, Noriaki; Miwa, Hiroto; Sugiyama, Yasuyuki; Kusano, Motoyasu

doi:10.1111/j.1440-1746.2008.05747.x

Cited by 59 publications

(53 citation statements)

References 29 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An investigation of the relationship between RE endoscopic findings and GERD symptoms also demonstrated that about 60% of RE relapsed cases had developed no GERD symptoms at the time of RE relapse. Several reports to date have also indicated that RE endoscopic findings were not accompanied by GERD symptoms (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35), and this trend was often found in elderly (28). It has also been reported that the percentage of severe RE is higher in the elderly than in juveniles, whereas the frequency of severe heartburn in patients with severe RE is lower in the elderly (27,36).…”

Section: Discussionmentioning

confidence: 91%

Safety and Efficacy of Long-Term Maintenance Therapy with Oral Dose of Rabeprazole 10 mg Once Daily in Japanese Patients with Reflux Esophagitis

Fujimoto

Hongo

Group³

2011

Intern. Med.

Self Cite

View full text Add to dashboard Cite

Objective The aim of this prospective clinical study was to evaluate the efficacy and safety of long-term proton pump inhibitor (PPI) treatment for two years in Japanese patients with reflux esophagitis (RE). Methods The efficacy and safety of two-year (104-week) treatment with rabeprazole (RPZ) 10 mg were studied in patients confirmed to have been cured of RE by PPI and who required long-term maintenance therapy with PPI. We performed serial endoscopy, checked gastroesophageal reflux disease (GERD) symptoms, adverse events, laboratory values and serum gastrin. We also monitored gastric mucosal histology, atrophy and polyps. Results The endoscopic non-relapse rate for RE was 87.3% for the 104-week period. GERD symptoms improved based on the fact that the mean change from baseline in GERD symptom score after treatment was a negative value. Treatment was safe; and atrophy was found to have developed in virtually no cases. A few new benign fundic gland or hyperplastic polyps developed throughout the study, but no ECL carcinoids were found to have developed. Serum gastrin levels tended to increase up to 24 weeks, but there were no subsequent changes thereafter up to 104 weeks. Conclusion The results confirmed oral RPZ 10 mg to be effective for maintenance therapy in Japanese patients with RE. Although effects on the gastric mucosa were not ruled out, long-term use of RPZ was confirmed to be safe overall.

show abstract

Section: Discussionmentioning

confidence: 91%

Safety and Efficacy of Long-Term Maintenance Therapy with Oral Dose of Rabeprazole 10 mg Once Daily in Japanese Patients with Reflux Esophagitis

Fujimoto

Hongo

Group³

2011

Intern. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…They reported that it showed a sensitivity of 62%, specificity of 59%, and accuracy of 60% when the c score was set at 8 points and F utoff SSG is widely used to evaluate GERD symptoms thereafter [13][14][15]. In this study, mean score of FSSG before starting the program was 8.6 and 30% of patients was equal or more than 8 points.…”

Section: Discussionmentioning

confidence: 87%

Quit smoking improves gastroesophageal reflux symptoms and quality of life

Nakajima¹,

Nagahara²,

Kurosawa³

et al. 2011

Health

View full text Add to dashboard Cite

Background: Smoking is considered to be risk factors of gastroesophageal reflux disease (GERD). The present study aimed to reveal whether quit smoking improves GERD symptoms and QOL of patients. Methods: In this prospective study, 33 patients who participated in a 12-week quit smoking program filled out the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire, and SF8 QOL questionnaire. Patients filled out the questionnaires at baseline and during the program at 2 weeks, 4 weeks, 8 weeks and 12 weeks. In the FSSG, the responses were scored and the reflux score (RS), dysmotility score (DS) and total score (TS) were calculated. Results: There were 22 males and 11 females. Their mean age was 54.8 ± 13.0 (mean ± SD) yr, BMI was 22.9 ± 4.0, and duration of smoking was 33.5 ± 12.5 years. Ten patients belonged to GERD subgroup (baselineFSSGscore ≥ 8). All patients were successful at quit smoking. Scores of TS/RS/DS are 8.6 ± 1.8 (mean ± SE)/4.2 ± 0.9/4.5 ± 0.9 at baseline, 4

show abstract

“…In patients with GERD, the FSSG score could be used to not only diagnose GERD but also assess the efficacy of PPI treatment for GERD [5].The symptom improvement rate of RPZ10mg daily dosing was 69.9% (107/153), a relatively favorable rate. No significant differences were observed between the prompt PPI treatment group (80.0%, 16/20) and the prompt endoscopy group (68.4%, 91/133)(p=0.43).However, performing prompt endoscopy can exclude malignant disorders and enable the diagnosis of GERD.…”

Section: Discussionmentioning

confidence: 99%

“…Subjects with scores≧ 8 were diagnosed with GERD. Symptom improvement was defined as scores of FSSG < 8 or ≧50% score reduction after dosing [5]. Each dropout stage on GERD-GL flowchart was defined as: stage 1; the patients couldn't be evaluated symptoms improvement after prompt PPI treatment; stage 2; the patients didn't visit hospital/clinic before PPI treatment on prompt endoscopy group; stage 3: the patients couldn't be followed up to long-term management after symptoms improvement on prompt endoscopy; stage 4;the patients didn't visit hospital/ clinic despite persisting symptoms after PPI treatment or were treated by the optional treatments; stage 5;PPI refractory GERD patients couldn't be followed up to long-term management after pathophysiologic evaluation (e.g.…”

Section: Methodsmentioning

confidence: 99%

Outcomes after GERD Treatment Based on the Japanese GERD Management Guideline

Koike¹

2015

JGPLD

View full text Add to dashboard Cite

show abstract

Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres

Abstract: The FSSG score reflects the severity of the endoscopic findings of GERD.

Cited by 59 publications

References 29 publications

Safety and Efficacy of Long-Term Maintenance Therapy with Oral Dose of Rabeprazole 10 mg Once Daily in Japanese Patients with Reflux Esophagitis

Safety and Efficacy of Long-Term Maintenance Therapy with Oral Dose of Rabeprazole 10 mg Once Daily in Japanese Patients with Reflux Esophagitis

Quit smoking improves gastroesophageal reflux symptoms and quality of life

Outcomes after GERD Treatment Based on the Japanese GERD Management Guideline

Contact Info

Product

Resources

About